Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: DPP-IVi, GLP-1RA, Topics Jun 28 | 2018Oral Semaglutide Superior to Januvia at 78 Weeks (PIONEER 3)Purchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery, Topics Jun 27 | 2018MannKind Re-Initiates TV DTC; Hosts Analyst MeetingPurchase Blast
$599
Posted in: SGLT2i, Topics Jun 25 | 2018BI/LLY Ph3 EASE Update – Jardiance in T1DMPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Jun 25 | 2018“Smart CGM is a new category” - Medtronic ADA 2018 investor event summaryPurchase Blast
$599
Posted in: GLP-1RA, SGLT2i, Topics Jun 24 | 2018ADA ’18 Key Data Press Releases (June 24)Purchase Blast
$599
Posted in: SGLT2i, Topics Jun 24 | 2018Imbalance in DKA Observed in DEPICT-2; Full 52-week inTandem1 dataPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Topics Jun 24 | 2018New Novo CVOT strategy; ADA '18 Analyst BriefingPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, SGLT2i, Topics Jun 23 | 2018Drug ADA ‘18 Key Data Press Releases (June 23)Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Jun 23 | 2018Devices/Apps ADA ’18 Key Data Press Releases (June 23)Purchase Blast$599
Posted in: GLP-1RA, Topics Jun 21 | 2018More Thoughts on PIONEER-4 and Potential Novo Regulatory Strategy for Oral SemaglutidePurchase Blast
$599
Posted in: Glucose Monitoring, Topics Jun 21 | 2018Senseonics Eversense CGM approved in the US; sPMA for insulin-dosing claim to followPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Jun 21 | 2018Tandem’s t:slim X2 pump approved with Basal-IQ; Medtronic 670G approved for ages 7-13Purchase Blast
$599
Posted in: Dual/triple agonist, Glucagon, Topics Jun 20 | 2018Novo Suspends Ph1 Stable Glucagon Analog StudyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other, Topics Jun 20 | 2018Voluntis and Monarch Medical Partnership Will Compete with GlytecPurchase Blast$599
Posted in: GLP-1RA, Topics Jun 20 | 2018Novo’s Oral Semaglutide Beats Victoza and JanuviaPurchase Blast
$599
Posted in: Other, Topics Jun 19 | 2018Novo Partners with Kallyope for Early-Stage Diabetes/Obesity R&DPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, Topics Jun 19 | 2018Thoughts on Glooko+DreaMed Data Services Franchise to Compete with Medtronic’s CareLinkPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Jun 19 | 2018Thoughts on Medtronic iPro2 Updated Professional CGM AppPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Jun 18 | 2018GlySens Implantable CGM Trial CompletedPurchase Blast$599
Posted in: Insulin Delivery, Topics Jun 18 | 2018Montreal dual-hormone AP System: Implications to Closed-Loop DevelopmentPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
